# Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

> **NCT02571712** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 750 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost 0.03% plus timolol 0.5%

## Key facts

- **NCT ID:** NCT02571712
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2018-06-21
- **Final completion:** 2018-06-21
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571712, "Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02571712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*